Biocon has announced a partnership with Juno Pharmaceuticals to market its liraglutide diabetes treatment in Canada, where the firms see a market worth as much as $100m.
Biocon Limited has signed a commercialization agreement with Juno Pharmaceuticals in Canada to market the Indian firm’s “vertically integrated, complex formulation” of liraglutide, a drug-device combination for the treatment and management of type 2 diabetes and obesity.
Under the terms of this deal, Biocon will be responsible for obtaining regulatory approval for liraglutide in Canada, as well...
Melinta Therapeutics has prevailed at the Federal Circuit in a patent dispute over its reformulated intravenous antibiotic Minocin, with the appeals court upholding both infringement and validity and leaving Nexus Pharmaceuticals barred from launching a generic until 2031.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
The UK government has said it will invest almost £30m ($40.4m) in AI technologies to modernize the NHS and reduce wait times – but for the medtech sector, the devil will be in the details.
Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains
